Recent discussions on X regarding Plus Therapeutics (PSTV) have centered around the company’s latest updates on its CNSide diagnostic platform, with several posts highlighting positive results presented at a prominent industry conference. Many users expressed intrigue over the platform’s potential to advance detection of central nervous system metastases, sparking conversations about its impact on the company’s future in the biotech space. The buzz reflects a keen interest in how these developments might influence the stock’s trajectory.
Additionally, there has been notable chatter about Plus Therapeutics’ compliance issues with Nasdaq listing requirements, as mentioned in recent posts on X. Some users have raised concerns about the reported stockholders’ equity deficit and the potential implications of a voluntary delisting, while others remain focused on the company’s ongoing projects. This mix of optimism and caution has created a dynamic dialogue among investors tracking the stock.
Note: This discussion summary was generated from an AI condensation of post data.
Plus Therapeutics Hedge Fund Activity
We have seen 9 institutional investors add shares of Plus Therapeutics stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC removed 560,905 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $532,915
- HRT FINANCIAL LP added 102,065 shares (+inf%) to their portfolio in Q1 2025, for an estimated $96,971
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 80,505 shares (+inf%) to their portfolio in Q1 2025, for an estimated $76,487
- UBS GROUP AG added 54,201 shares (+162.1%) to their portfolio in Q2 2025, for an estimated $18,851
- VIRTU FINANCIAL LLC removed 40,030 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $13,922
- GEODE CAPITAL MANAGEMENT, LLC removed 5,877 shares (-10.3%) from their portfolio in Q2 2025, for an estimated $2,044
- TOWER RESEARCH CAPITAL LLC (TRC) added 2,894 shares (+60.5%) to their portfolio in Q1 2025, for an estimated $2,749
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Plus Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $PSTV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/27/2025
- Ascendiant Capital issued a "Buy" rating on 06/05/2025
To track analyst ratings and price targets for Plus Therapeutics, check out Quiver Quantitative's $PSTV forecast page.
Plus Therapeutics Price Targets
Multiple analysts have issued price targets for $PSTV recently. We have seen 3 analysts offer price targets for $PSTV in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Sean Lee from HC Wainwright & Co. set a target price of $3.0 on 06/27/2025
- Jason Kolbert from D. Boral Capital set a target price of $9.0 on 06/25/2025
- Edward Woo from Ascendiant Capital set a target price of $20.5 on 06/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
